

## Anti-DLL4 Antibody (Navicixizumab)

### Introduction

Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can be used in combination with paclitaxel for cancer research. Navicixizumab can be used in the study of ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

### Product parameters

Alternative Names	OMP-305B83
Target Accession	Q9NR61
Target	DLL4
CAS number	1638338-43-8
Molecular Weight	146.17 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG2SA
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human VEGF165 His at 2 ug/mL can bind Anti-DLL4 Antibody (Navicixizumab), EC50=0.01191 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



### **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

